Radiation-based Solutions for Diverse Industries
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of the original patent to develop novel applications in water treatment, medical instrument sterilization, surface decontamination, agricultural produce treatment, and industrial process microbial growth reduction.
Background and Problem Solved
The original patent's alpha-emitter radiation therapy with enhanced beta treatment has limitations in its applicability to other fields. This inventive concept addresses the need for innovative solutions in various industries, where the unique properties of alpha-emitting atoms can be harnessed to provide effective radiation-based treatments.
Detailed Description of the Inventive Concept
The new claims describe systems and methods that utilize alpha-emitting atoms with a desorption probability of at least 1% but less than 30%, attached to a support with an inner coating and an outer coating. These radiation sources are designed to provide a predetermined dosage of beta radiation to target specific applications. For instance, the water treatment system incorporates the radiation source to eliminate waterborne pathogens, while the medical instrument sterilization method utilizes the radiation source to ensure aseptic conditions. Similarly, the surface decontamination device, agricultural produce treatment system, and industrial process microbial growth reduction method all exploit the benefits of controlled beta radiation.
Novelty and Inventive Step
The new claims introduce a novel application of the original patent's technology, expanding its scope to diverse industries. The inventive step lies in the recognition of the alpha-emitting atoms' potential in these new fields and the development of tailored systems and methods to harness their benefits.
Alternative Embodiments and Variations
Alternative embodiments may include variations in the support materials, coating configurations, and radiation source designs. Additionally, the inventive concept could be adapted for use in other industries, such as food processing, cosmetics, or pharmaceuticals, where controlled beta radiation can provide unique advantages.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various industries, including water treatment, healthcare, agriculture, and industrial processes. The market demand for innovative, radiation-based solutions is substantial, and this concept is poised to capitalize on these opportunities, offering a competitive edge in terms of effectiveness, efficiency, and safety.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Radiation therapy and radiation source technologies, specifically involving alpha-emitting atoms and radiation-based treatment systems. Requires expertise in radioisotope engineering, radiation physics, materials science, and medical/industrial radiation applications
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in physics, engineering, or radiation sciences, possessing knowledge of radiation source design, isotope behavior, coating technologies, and cross-industry radiation applications. Capable of understanding radiation dosage control, material interactions, and adaptive radiation source configurations
Obviousness Rationale
A PHOSITA would recognize that the source patent's core radiation technology provides a foundational framework for diverse applications beyond medical treatment. The PTD's variations represent predictable extensions of the original radiation source design, applying known radiation principles to different industrial contexts using substantially identical technical mechanisms. The modifications primarily involve adapting the radiation source's positioning and control parameters rather than fundamentally altering the underlying radiation technology.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,803 |
|---|---|
| Title | Diffusing alpha-emitter radiation therapy with enhanced beta treatment |
| Assignee(s) | Alpha Tau Medical Ltd |